The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

The present invention provides mammalian cell lines that have been genetically engineered causing such cell lines to be resistant to viral entry and/or propagation, and provides methods of using said cell lines to reduce or prevent viral contamination of biologic production systems.

The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

A reactive compound is made of modified trimannose-oligosaccharides. Methods are for preparing and using modified trimannose-oligosaccharides. The compounds and methods are for improving the characteristics of a first ligand of interest, especially in therapeutic or diagnostic applications. In particular, a reactive compound includes a trimannose core of formula 1

##STR00001## wherein Man.sup.1, Man.sup.2 and Man.sup.3 moieties are a first, a second and a third mannose, respectively, R.sub.1 is a linking group able to bind or binding the GlcNAc group to a first ligand of interest, R.sub.2 and R.sub.3 are monosaccharides or derivatives thereof, optionally linked to one or more additional saccharide(s). GlcNAz is an unnatural N-Azidoacetylglucosamine group able to bind or binding to a second ligand of interest different from the first ligand of interest.

The present disclosure relates to multispecific (e.g., bispecific) binding proteins that bind human Dectin-1 and human CD20, and methods of use and production related thereto.